Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

The Global Drug sales of Herceptin (2017 - 2025, USD Millions)

  • The Global Drug sales of Herceptin stood at USD 3,976.47 Millions in 2020

  • The indicator recorded a historical decline (CAGR) of18% between 2017 to 2020 and is expected to decline by ...

  • GlobalData projects the indicator to decline at a CAGR of...

Get access to more granular statistics data when you subscribe Get access to more granular statistics data when you subscribe Learn More

The Global Drug sales of Herceptin (2017 - 2025, USD Millions)

Published: Nov 2021
Source: GlobalData

Unlock Forecasts and Access to 55 Million Statistics for >20 Industries, for $700 a month

Trastuzumab (Herceptin) is a humanized IgG1 kappa monoclonal antibody. It is formulated as freeze-dried powder for solution for intravenous administration and solution for subcutaneous, intravenous route of administration.

Mechanism of Action
Trastuzumab is cytotoxic to cells expressing human epidermal growth factor receptor 2. The drug inhibits the proliferation of human tumor cells that overexpress HER2. The drug acts as mediator of antibody-dependent cellular cytotoxicity. Trastuzumab binds to the HER2 (c-erbB2) proto-oncogene, an EGF receptor-like protein found in breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells.

Herceptin Overview

Herceptin is marketed for several indications in oncology therapy area.

Herceptin is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer, in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable, in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease, adult patients with HER2 positive early breast cancer, in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic gentamicin. The drug candidate is based on enhanze technology which is a drug delivery platform designed to increase the absorption and dispersion of biologics.

Herceptin was first approved in 1998 and is sold globally including the US, the UK, France, Germany, and Japan by F. Hoffmann-La Roche Ltd and its subsidiaries. Herceptin drug sales recorded a low-double digit Year on Year decline in 2021. Herceptin drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology. 

 



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward